Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Nomura, Johji ^a,b   Busso, Nathalie ^b   Ives, Annette ^b   Matsui, Chieko ^a   Tsujimoto, Syunsuke ^a   Shirakura, Takashi ^a   Tamura, Mizuho ^a   Kobayashi, Tsunefumi ^a   So, Alexander ^b   Yamanaka, Yoshihiro ^a  

^a TEIJIN LTD   (Japan)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; APOLIPOPROTEIN E; CHOLESTEROL; CYTOKINE; FEBUXOSTAT; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; THIAZOLE DERIVATIVE; XANTHINE OXIDASE;

ANIMAL; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; BLOOD; BODY WEIGHT; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY; SECRETION (PROCESS);

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BODY WEIGHT; CHOLESTEROL; CYTOKINES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GOUT SUPPRESSANTS; INFLAMMATION; L-LACTATE DEHYDROGENASE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; REACTIVE OXYGEN SPECIES; THIAZOLES; XANTHINE OXIDASE;

EID: 84897410215     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04554     Document Type: Article

References (38)

1. Yang, Z. & Ming, X. F. Arginase: the emerging therapeutic target for vascular oxidative stress and inflammation. Front Immunol 4, 149 (2013).
2. Lonn, M. E., Dennis, J. M. & Stocker, R. Actions of "antioxidants" in the protection against atherosclerosis. Free Radic Biol Med 53, 863-84 (2012).
3. Riccioni, G. & Sblendorio, V. Atherosclerosis: from biology to pharmacological treatment. J Geriatr Cardiol 9, 305-17 (2012).
4. Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nat Immunol 12, 204-12 (2011).
5. Mudau, M., Genis, A., Lochner, A. & Strijdom, H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr 23, 222-31 (2012).
6. Munzel, T., Gori, T., Bruno, R. M. & Taddei, S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 31, 2741-8 (2010).
7. Nishino, T., Okamoto, K., Eger, B. T., Pai, E. F. & Nishino, T. Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 275, 3278-89 (2008). (Pubitemid 351813552)
8. Patetsios, P. et al. Identification of uric acid and xanthine oxidase in atherosclerotic plaque. Am J Cardiol 88, 188-91, A6 (2001). (Pubitemid 32607712)
9. Kushiyama, A. et al. Xanthine oxidoreductase is involved in macrophage foam cell formation and atherosclerosis development. Arterioscler Thromb Vasc Biol 32, 291-8 (2012).
10. Schroder, K. et al. Xanthine oxidase inhibitor tungsten prevents the development of atherosclerosis in ApoE knockout mice fed aWestern-type diet. Free Radic Biol Med 41, 1353-60 (2006). (Pubitemid 44479882)
11. Nomura, J. et al. Febuxostat, an Inhibitor of Xanthine Oxidase, Suppresses Lipopolysaccharide-Induced MCP-1 Production via MAPK Phosphatase-1-Mediated Inactivation of JNK. PLoS One 8, e75527 (2013).
12. Shimada, K. et al. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E-deficient mice by reducing superoxide production. Circ J 73, 1337-41 (2009).
13. Kinoshita, H. et al. Apocynin suppresses the progression of atherosclerosis in apoE-deficient mice by inactivation of macrophages. Biochem Biophys Res Commun 431, 124-30 (2013).
14. Okabe, T. A. et al. Effects of MCI-186 (edaravone), a novel free radical scavenger, upon experimental atherosclerosis in apolipoprotein E-deficient mice. Circ J 70, 1216-9 (2006).
15. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-61 (2010).
16. Sheedy, F. J. et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 14, 812-20 (2013).
17. Rajamaki, K. et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 5, e11765 (2010).
18. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11, 136-40 (2010).
19. Yin, Y. et al. Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci 18, 638-49 (2013).
20. Inoue, S. et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein Eknockout mice. Circulation 106, 2700-6 (2002). (Pubitemid 35364925)
21. Freigang, S. et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat Immunol 14, 1045-53 (2013).
22. Freigang, S. et al. Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 41, 2040-51 (2011).
23. Park, J. G. et al. Evaluation of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 226, 356-63 (2013).
24. Forstermann, U. & Sessa, W. C. Nitric oxide synthases: regulation and function. Eur Heart J 33, 829-37, 837a-837d (2012).
25. Madigan, M. & Zuckerbraun, B. Therapeutic Potential of the Nitrite-Generated NO Pathway in Vascular Dysfunction. Front Immunol 4, 174 (2013).
26. Lin, J. et al. Oxidized low density lipoprotein induced caspase-1 mediated pyroptotic cell death in macrophages: implication in lesion instability? PLoS One 8, e62148 (2013).
27. Menu, P. et al. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis 2, e137 (2011).
28. Usui, F. et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun 425, 162-8 (2012).
29. Gross, O., Thomas, C. J., Guarda, G. & Tschopp, J. The inflammasome: an integrated view. Immunol Rev 243, 136-51 (2011).
30. Liu, C. et al. Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica. J Clin Neurosci 20, 278-80 (2013).
31. Peng, F. et al. Serum uric acid levels and neuromyelitis optica. J Neurol 257, 1021-6 (2010).
32. Amaro, S. et al. Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke 42, S28-32 (2011).
33. Miedema, I. et al. Lack of association between serum uric acid levels and outcome in acute ischemic stroke. J Neurol Sci 319, 51-5 (2012).
34. Garcia-Valladares, I., Khan, T. & Espinoza, L. R. Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Ther Adv Musculoskelet Dis 3, 245-53 (2011).
35. Ye, P. et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther 35, 180-9 (2013).
36. Malik, U. Z. et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 51, 179-84 (2011).
37. Sezai, A. et al. Comparison of Febuxostat and Allopurinol for Hyperuricemia in Cardiac Surgery Patients (NU-FLASH Trial). Circ J 77, 2043-9 (2013).
38. Beckman, J. S., Parks, D. A., Pearson, J. D., Marshall, P. A. & Freeman, B. A. A sensitive fluorometric assay for measuring xanthine dehydrogenase and oxidase in tissues. Free Radic Biol Med 6, 607-15 (1989). (Pubitemid 19147811)